Premium
Hypercalcemia and 13‐ cis ‐retinoic acid in post‐consolidation therapy of neuroblastoma
Author(s) -
Marabelle Aurélien,
Sapin Vincent,
Rousseau Raphaël,
Periquet Brigitte,
Demeocq François,
Kanold Justyna
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21768
Subject(s) - medicine , neuroblastoma , retinoic acid , consolidation (business) , cancer research , oncology , biochemistry , genetics , chemistry , biology , gene , cell culture , accounting , business
We report 19 episodes of hypercalcemia in three children treated with 13‐ cis ‐retinoic acid (13‐ cis ‐RA) as a post‐consolidation therapy for high‐risk neuroblastoma. There was no concomitant overload in 13‐ cis ‐RA blood levels. Blood calcium fell after arrest of 13‐ cis ‐RA intake. Half dosage retinoid treatment resumption did not prevent the recurrence of hypercalcemia. Concomitant biological values showed massive bone resorption. Hence, hypercalcemia seemed not secondary to 13‐ cis ‐RA overload but rather to inter‐individual variability in its interaction with bone metabolism. Current guidelines in case of hypercalcemia are to reduce 13‐ cis ‐RA dosage. Instead we propose to maintain the therapeutic dosage, but to shorten the duration of courses. Pediatr Blood Cancer 2009;52:280–283. © 2008 Wiley‐Liss, Inc.